Zurawski V R, Knapp R C, Einhorn N, Kenemans P, Mortel R, Ohmi K, Bast R C, Ritts R E, Malkasian G
Gynecologic Oncology Laboratories, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115.
Gynecol Oncol. 1988 May;30(1):7-14. doi: 10.1016/0090-8258(88)90039-x.
Preoperative serum CA 125 levels were determined for 36 patients with Stage I and II ovarian carcinoma. Levels ranged from 9 to 1962 U/ml with a mean of 216 U/ml. In Stage I patients, CA 125 levels averaged 133 U/ml and in Stage II patients 382 U/ml. Nine of 24 Stage I (38%) and 9 of 12 Stage II patients (75%) had CA 125 levels in excess of 65 U/ml in a population somewhat overrepresented in mucinous tumors. Patients with non-mucinous neoplasms had CA 125 elevations more often--in 75% of the cases--than those with mucinous tumors. A larger study will be required to more precisely estimate the fraction of early stage patients with elevated preoperative serum CA 125 levels; however, this investigation demonstrates an assay sensitivity minimally adequate to initiate a pilot evaluation of serum CA 125 levels in a population at risk for ovarian carcinoma.
对36例Ⅰ期和Ⅱ期卵巢癌患者测定了术前血清CA 125水平。水平范围为9至1962 U/ml,平均为216 U/ml。在Ⅰ期患者中,CA 125水平平均为133 U/ml,在Ⅱ期患者中为382 U/ml。在黏液性肿瘤略多的人群中,24例Ⅰ期患者中有9例(38%)以及12例Ⅱ期患者中有9例(75%)的CA 125水平超过65 U/ml。非黏液性肿瘤患者的CA 125升高更为常见——在75%的病例中——高于黏液性肿瘤患者。需要进行更大规模的研究,以更精确地估计术前血清CA 125水平升高的早期患者比例;然而,本研究表明该检测方法的敏感性至少足以启动对卵巢癌高危人群血清CA 125水平的初步评估。